S-1: Aethlon Medical Registers 2M Shares for Resale

Aethlon Medical, Inc. filed an S-1 registration statement for the resale of up to 2,031,024 shares of common stock underlying various warrants, primarily from a December 2025 private placement.

Summary

• The company filed an S-1 registration statement for the resale of up to 2,031,024 shares of common stock by selling securityholders.
• These shares are issuable upon the exercise of Common Warrants (1,042,820 shares), Pre-Funded Warrants (595,897 shares), Inducement Warrants (368,471 shares), and Placement Agent Warrants (23,836 shares).
• The Common Warrants and Inducement Warrants have an exercise price of $4.03 per share, while Placement Agent Warrants have an exercise price of $5.04 per share. The Pre-Funded Warrants have a nominal exercise price of $0.0001 per share.
• As of January 5, 2026, the last reported sale price of the company's common stock on Nasdaq was $2.75 per share, making most warrants out-of-the-money.
• The warrants require 'Warrant Stockholder Approval' from Nasdaq to become exercisable, and there is no guarantee this approval will be obtained.
• The company will not receive proceeds from the resale of shares by selling securityholders, but may receive proceeds from cash exercises of the warrants, though this is unlikely for most due to current stock price.
• Aethlon Medical is a clinical-stage immunotherapeutic device company developing the Hemopurifier for cancer, life-threatening viral infections, and organ transplantation.
• The Hemopurifier has received FDA Breakthrough Device designation for two independent indications: advanced/metastatic cancer and life-threatening viruses not addressed by approved therapies.
• The company is conducting a Phase 1 safety, feasibility, and dose-finding clinical trial in Australia for cancer patients with solid tumors, with the DSMB recommending advancement to the next cohort on July 15, 2025.
• Formal approval has been received from the India Regulatory Agency CDSCO to commence a similar clinical trial in India.
• Pre-clinical studies have shown the Hemopurifier's potential to remove harmful exosomes and platelet-derived extracellular vesicles (EVs).
• Research and development expenses were approximately $2,212,000 for the fiscal year ended March 31, 2025, and $818,686 for the six-month period ended September 30, 2025.
• The company owns or licenses a portfolio of over 32 issued patents and pending applications worldwide related to its Hemopurifier technology.

Sentiment

Score: 3

Explanation: While there are positive clinical and regulatory developments for the Hemopurifier, the immediate financial implications of this S-1 filing are negative due to the out-of-the-money warrants and the company's going concern warning. The potential for significant dilution and limited capital inflow from the warrant exercises overshadows the clinical progress in the short term.

Positives

• The Hemopurifier has received FDA Breakthrough Device designation for two independent indications: advanced/metastatic cancer and life-threatening viruses.
• Pre-clinical studies demonstrated the Hemopurifier's potential to remove harmful exosomes and exosomal particles from biological fluids, supporting its applications in cancer and infectious diseases.
• An in vitro binding study indicated positive results, providing evidence that the Hemopurifier removes extracellular vesicles (EVs) from plasma.
• A Phase 1 safety, feasibility, and dose-finding clinical trial for the Hemopurifier in cancer patients with solid tumors is ongoing in Australia, with three hospitals open for enrollment.
• The Data Safety Monitoring Board (DSMB) overseeing the Australian clinical trial (AEMD-2022-06) completed its scheduled safety review on July 15, 2025, and recommended advancing to the next patient cohort without modification.
• Formal approval has been received from the India Regulatory Agency CDSCO to commence a similar clinical trial at Medanta Medicity Hospital in India.
• A pre-clinical ex vivo study published in bioRxiv showed a 98.5% removal of platelet-derived EVs from plasma, supporting investigation of the Hemopurifier in many indications, including Long COVID.
• The company maintains an open Investigational Device Exemption (IDE) for viral indications, preserving optionality for future outbreaks or emergent pathogens.
• Sufficient inventory of Hemopurifiers is available to support ongoing oncology trials in Australia and potential expansion to India.
• The FDA approved the use of the company's own manufacturing facility to manufacture Hemopurifiers in May 2024.
• The company has a robust intellectual property portfolio with over 32 issued patents and pending applications worldwide, including 3 issued U.S. patents and 14 issued foreign patents.

Negatives

• The Common Warrants, Inducement Warrants, and Placement Agent Warrants have exercise prices ($4.03 and $5.04 per share) significantly higher than the common stock's last reported sale price ($2.75 per share on January 5, 2026), making cash exercise by selling securityholders unlikely.
• The company will not receive meaningful additional funds from the exercise of the Pre-Funded Warrants due to their nominal exercise price of $0.0001 per share.
• The warrants are not exercisable until 'Warrant Stockholder Approval' is obtained, and there is no guarantee this approval will be secured, potentially rendering the common warrants valueless.
• The company's auditors have included an explanatory paragraph in their report expressing 'substantial doubt' about the company's ability to continue as a going concern.
• The termination of U.S. and India-based COVID-19 studies was due to low ICU patient volume and shifting priorities, indicating challenges in clinical trial execution for certain indications.
• The company is dependent on a single supplier (Medica S.p.A) for a critical base cartridge component of the Hemopurifier.
• There is a delay in qualifying an additional supplier for a key Hemopurifier component due to pending FDA approval of a supplement to the company's IDE.
• The company faces a high degree of uncertainty and risk regarding the duration and impact of inflation, recent bank failures, and ongoing military conflicts on capital markets and future access to capital.
• The industry for treating infectious disease and cancer is extremely competitive, posing significant capital and regulatory challenges.
• The company currently lacks sales and marketing capabilities and will need to build or contract for these in the future for commercialization.
• Limited clinical trial liability insurance coverage exists, and future coverage may be inadequate or unavailable on acceptable terms, exposing the company to substantial monetary awards from product liability claims.

Risks

• The Common Warrants, Inducement Warrants, and Placement Agent Warrants are currently worth less than their exercise price, making cash exercise by Selling Securityholders unlikely and limiting potential cash proceeds to the company.
• Investors purchasing shares at different times may pay different prices and experience varying levels of dilution and investment outcomes.
• Future sales of substantial amounts of common stock could adversely affect the market price of the common stock.
• Raising additional capital through equity or convertible debt securities could result in further dilution to investors and downward pressure on the stock price.
• The company will not receive any meaningful amount of additional funds upon the exercise of the Pre-Funded Warrants due to their nominal exercise price.
• The Common Warrants, Inducement Warrants, Pre-Funded Warrants, and Placement Agent Warrants will not be exercisable unless and until stockholder approval is obtained, and if not obtained, the common warrants will have no value.
• The company may incur substantial costs and management time in attempting to obtain the required Warrant Stockholder Approval.
• The ability to successfully commercialize products and technology, including the Hemopurifier, is uncertain.
• The company's ability to raise additional capital to meet working capital needs is a significant risk.
• The timing and results of future clinical trials are uncertain, and the company may not successfully complete them.
• The ability to identify and work with large-scale contracts with medical device manufacturers is critical for future operations.
• The company's ability to manufacture the Hemopurifier on a large scale is a risk.
• The impact of inflation, recent bank failures, and military conflicts, as well as related political and economic responses, on the company's business, timelines, and future access to capital is highly uncertain.
• The company's ability to attract and retain executive management and directors is crucial.
• The regulatory landscape for products, domestically and internationally, is complex and subject to change, impacting the company's ability to comply.
• The company must comply with the continued listing requirements of the Nasdaq Capital Market to maintain its listing.
• There are uncertainties regarding the growth potential for the company's business in the organ transplant setting.
• The company's ability to secure regulatory clearance or approval, domestically and internationally, for the clinical use of its products is not guaranteed.
• Estimates regarding expenses, future revenue, and capital requirements are subject to uncertainty.
• The company's ability to protect its proprietary technology through patent protection is vital but faces challenges from potential invalidation, infringement, or independent development by competitors.
• Product liability exposure is inherent in the medical products industry, and future insurance coverage may be inadequate.
• The company's ability to sustain and manage growth, including developing new products and entering new markets, is a risk.
• Achieving sufficient market acceptance of any of the company's products or product candidates is uncertain.
• The trading price of the company's common stock has been volatile and is subject to wide fluctuations.
• The potential effects of government regulation, including healthcare reform measures, could adversely impact the business.
• The company's reliance on unpatented trade secrets and proprietary technological expertise may not be fully protected.
• The Hemopurifier is expected to be classified as a Class III device, requiring a demanding Pre-Market Approval (PMA) process that can take several years.
• Even after a device receives clearance or approval, numerous ongoing regulatory requirements apply, and failure to comply can result in enforcement actions.
• The FDA prohibits marketing an approved device for off-label use, and improper promotion can lead to significant liability.
• The use of medical devices is dependent on the availability of reimbursement from third-party payors, and the Hemopurifier may not be considered cost-effective or receive sufficient reimbursement.
• The company is dependent on limited available suppliers for critical components of the Hemopurifier, and qualifying new suppliers takes time and regulatory approvals.

Future Outlook

The company plans to expand its clinical trials by opening a similarly designed study in India for cancer patients. It intends to maintain an open IDE for viral indications to retain flexibility for future outbreaks or emergent pathogens. The R&D laboratory will continue to explore new potential indications for the Hemopurifier, including applications in Long COVID. For commercialization, the company aims to build or contract for necessary distribution, sales, and marketing capabilities for any approved product candidates. The company is also monitoring global economic and political events for their potential impact on timelines and future access to capital.

Management Comments

• We believe that the Hemopurifier may be a substantial advancement in the treatment of patients with advanced and metastatic cancer through its design to bind to and remove harmful extracellular vesicles particles that promote the growth and spread of tumors.
• We believe that the Hemopurifier can be part of the broad-spectrum treatment of life-threatening highly glycosylated, or carbohydrate coated, viruses that are not addressed with an already approved treatment.
• We believe the data from this pre-clinical study calls for additional study of the Hemopurifier and look forward to receiving feedback from the Long COVID scientific community at the Keystone Symposium.
• We believe that certain patent applications and/or other patents issued to us more recently will help protect the proprietary nature of our Hemopurifier treatment technology.
• We believe our employee relations are good.

Industry Context

Aethlon Medical operates in the highly competitive medical therapeutic industry, specifically targeting infectious diseases and cancer. This sector is characterized by significant capital requirements and stringent regulatory hurdles. The company's focus on a clinical-stage immunotherapeutic device, the Hemopurifier, necessitates establishing strong medical industry support through robust human clinical study data. Competitors include other blood filter manufacturers like ExThera Medical Corporation. The broader healthcare landscape is trending towards cost containment, with government and private insurers seeking to control costs through lower payment rates, which could impact the market adoption and profitability of new medical devices. Recent legislative changes, such as the Inflation Reduction Act of 2022, are also reshaping drug pricing and reimbursement policies, potentially affecting the pharmaceutical and medical device industries.

Comparison to Industry Standards

• The Hemopurifier has received FDA Breakthrough Device designation for two indications, which is a significant achievement in the medical device industry, indicating its potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
• The company's ongoing Phase 1 clinical trials in Australia and planned trials in India for oncology applications are standard approaches for medical device companies to gather safety and efficacy data in human subjects.
• The company identifies ExThera Medical Corporation as a competitor producing blood filters, indicating a competitive landscape for extracorporeal devices, though specific comparative performance data is not provided in the filing.

Corporate Governance

Stakeholder Impact

• **Shareholders**: Face potential significant dilution if all 2,031,024 shares underlying the warrants are issued and resold. The current market price being below the exercise price of most warrants means limited immediate capital inflow for the company, but the possibility of future dilution remains. The 'going concern' warning from auditors indicates heightened risk to investment value.
• **Investors (in this offering)**: May experience a decline in the value of shares purchased due to sales by the company in future transactions at lower prices. They may also pay different prices depending on the timing of their purchases.
• **Employees**: The company intends to hire additional employees, suggesting potential for growth and job opportunities, but the overall financial health and 'going concern' warning could create uncertainty.
• **Customers/Patients**: The continued development of the Hemopurifier, particularly with FDA Breakthrough Device designations and ongoing clinical trials in cancer and viral infections, offers potential for new therapeutic options for life-threatening conditions.
• **Creditors**: The 'substantial doubt' about the company's ability to continue as a going concern increases the risk for creditors regarding the repayment of debts.

Next Steps

• Hold an Annual Meeting of stockholders around February 2026 to seek 'Warrant Stockholder Approval' for the exercisability of warrants.
• If initial stockholder approval is not obtained, the company is obligated to hold additional stockholder meetings every 180 days thereafter until approval is secured.
• Continue the ongoing Phase 1 safety, feasibility, and dose-finding clinical trials for the Hemopurifier in cancer patients with solid tumors in Australia.
• Commence the clinical trial at Medanta Medicity Hospital in India following a Site Initiation Visit (SIV) by the company's India CRO, Qualtran.
• Continue working with the FDA to obtain approval for a supplement to qualify an additional supplier of a key Hemopurifier component.
• Explore potential new indications for the Hemopurifier in the R&D laboratory, including applications related to Long COVID.
• Receive feedback from the Long COVID scientific community at the Keystone Symposium.
• Build or contract for distribution, sales, and marketing capabilities for any product candidates that receive regulatory approval.
• Monitor the impact of inflation, recent bank failures, and ongoing military conflicts on the business, results of operations, financial condition, clinical trials, preclinical research, and future access to capital.
• Seek additional patents on scientific discoveries to protect proprietary technology.

Key Dates

Recommendation

The S-1 filing reveals critical financial weaknesses and risks that outweigh the positive clinical developments. The company's auditors have issued a 'going concern' warning, indicating significant financial instability. The majority of the warrants registered for resale are deeply out-of-the-money, meaning the company is unlikely to receive substantial cash proceeds from their exercise, which would otherwise provide much-needed capital. This situation, combined with the potential for significant dilution from the resale of shares and the uncertainty surrounding stockholder approval for warrant exercisability, creates a highly unfavorable investment profile. While the Hemopurifier shows promise, the immediate financial outlook and capital structure risks suggest a 'sell' recommendation for seasoned investors.

Keywords

Aethlon Medical, Hemopurifier, S-1 Registration, Warrants, Common Stock Resale, Nasdaq, Clinical Trials, Oncology, Viral Infections, Extracellular Vesicles, Exosomes, Immunotherapeutic Device, FDA Breakthrough Device, Medical Device, Biotechnology, Healthcare, Patent, Intellectual Property, Dilution, Capital Raise, Going Concern